Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. (Q51317570)
Jump to navigation
Jump to search
scientific article published on 9 July 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. |
scientific article published on 9 July 2014 |
Statements
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. (English)
1 reference
Peter Stein
1 reference
Jolene K Berg
1 reference
Linda Morrow
1 reference
David Polidori
1 reference
Eunice Artis
1 reference
Sarah Rusch
1 reference
Nicole Vaccaro
1 reference
Damayanthi Devineni
1 reference
9 July 2014
1 reference
63
1 reference
10
1 reference
1296-1303
1 reference